Assenagon Asset Management
BCRX icon

Assenagon Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Assenagon Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.53M Buy
353,044
+120,097
+52% +$1.09M ﹤0.01% 729
2026
Q1 		$2.22M Sell
232,947
-126,633
-35% -$983K ﹤0.01% 763
2025
Q4 		$2.8M Sell
359,580
-2,733,012
-88% -$19.8M ﹤0.01% 785
2025
Q3 		$23.5M Sell
3,092,592
-528,045
-15% -$4.4M 0.03% 339
2025
Q2 		$32.4M Buy
3,620,637
+3,606,566
+25,631% +$33.6M 0.05% 285
2025
Q1 		$106K Hold
14,071
– – ﹤0.01% 1130
2024
Q4 		$106K Hold
14,071
– – ﹤0.01% 1293
2024
Q3 		$107K Sell
14,071
-50,836
-78% -$386K ﹤0.01% 1346
2024
Q2 		$401K Sell
64,907
-321,978
-83% -$1.78M ﹤0.01% 1269
2024
Q1 		$1.97M Sell
386,885
-142,534
-27% -$802K ﹤0.01% 904
2023
Q4 		$3.17M Sell
529,419
-580,485
-52% -$3.36M 0.01% 768
2023
Q3 		$7.86M Sell
1,109,904
-4,223,010
-79% -$30.3M 0.02% 446
2023
Q2 		$37.5M Buy
5,332,914
+365,077
+7% +$2.93M 0.13% 134
2023
Q1 		$41.4M Buy
4,967,837
+2,377,445
+92% +$22.9M 0.15% 129
2022
Q4 		$29.7M Sell
2,590,392
-25,765
-1% -$321K 0.11% 194
2022
Q3 		$33M Sell
2,616,157
-561,714
-18% -$7.23M 0.13% 156
2022
Q2 		$33.6M Buy
3,177,871
+3,107,027
+4,386% +$32.1M 0.12% 158
2022
Q1 		$1.15M Buy
70,844
+57,608
+435% +$924K ﹤0.01% 1019
2021
Q4 		$183K Sell
13,236
-53,891
-80% -$713K ﹤0.01% 1381
2021
Q3 		$965K Sell
67,127
-687,905
-91% -$10.8M ﹤0.01% 915
2021
Q2 		$11.9M Buy
755,032
+710,563
+1,598% +$9.65M 0.04% 307
2021
Q1 		$452K Buy
+44,469
New +$459K ﹤0.01% 1042
2020
Q3 		– Sell
-303,400
Closed -$1.45M – 1129
2020
Q2 		$1.45M Buy
+303,400
New +$1.21M 0.01% 690
2020
Q1 		– Sell
-74,744
Closed -$258K – 798
2019
Q4 		$258K Buy
+74,744
New +$188K ﹤0.01% 715

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Assenagon Asset Management's BCRX Position: Q2 2026 in Review

Assenagon Asset Management increased its BioCryst Pharmaceuticals (BCRX) stake by 52% in Q2 2026, buying an estimated $1.09M and bringing the position to 353,044 shares worth $3.53M. The position accounts for ﹤0.01% of the portfolio, ranked #729.

Assenagon Asset Management first reported a position in BCRX in Q4 2019 and has held it in 24 quarters since. The position peaked at $41.4M in Q1 2023. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Assenagon Asset Management held 353,044 shares of BioCryst Pharmaceuticals worth $3.53M as of Q2 2026.
  • Assenagon Asset Management bought 120,097 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.09M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #729 holding.
  • Assenagon Asset Management first reported a position in BioCryst Pharmaceuticals in Q4 2019 and has held it in 24 quarters since.
  • Assenagon Asset Management's BioCryst Pharmaceuticals position peaked at $41.4M in Q1 2023.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.